Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) up 0.1%.
Arcellx (ACLX) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.
Agios Pharmaceuticals (AGIO) shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.
Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。